Syverson Strege & Co Buys Shares of 853 Cencora, Inc. $COR

Syverson Strege & Co bought a new stake in shares of Cencora, Inc. (NYSE:COR) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 853 shares of the company’s stock, valued at approximately $256,000.

Several other large investors have also modified their holdings of the business. Atlantic Edge Private Wealth Management LLC boosted its position in shares of Cencora by 70.0% during the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after buying an additional 35 shares during the period. Obermeyer Wealth Partners boosted its position in shares of Cencora by 1.3% during the first quarter. Obermeyer Wealth Partners now owns 2,724 shares of the company’s stock valued at $758,000 after buying an additional 36 shares during the period. Grove Bank & Trust boosted its position in shares of Cencora by 4.3% during the second quarter. Grove Bank & Trust now owns 879 shares of the company’s stock valued at $264,000 after buying an additional 36 shares during the period. U.S. Capital Wealth Advisors LLC boosted its position in shares of Cencora by 0.4% during the second quarter. U.S. Capital Wealth Advisors LLC now owns 8,547 shares of the company’s stock valued at $2,563,000 after buying an additional 38 shares during the period. Finally, Monument Capital Management boosted its position in shares of Cencora by 2.4% during the second quarter. Monument Capital Management now owns 1,637 shares of the company’s stock valued at $491,000 after buying an additional 38 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Wall Street Zen lowered Cencora from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Mizuho boosted their target price on Cencora from $334.00 to $340.00 and gave the company an “outperform” rating in a research report on Thursday. Wells Fargo & Company boosted their target price on Cencora from $337.00 to $354.00 and gave the company an “overweight” rating in a research report on Wednesday, August 13th. Evercore ISI set a $340.00 price target on shares of Cencora in a research note on Wednesday, October 8th. Finally, UBS Group lifted their price target on shares of Cencora from $350.00 to $380.00 and gave the company a “buy” rating in a research note on Monday. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $329.55.

Insider Buying and Selling

In related news, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction that occurred on Monday, October 20th. The shares were sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the transaction, the chief executive officer owned 37,940 shares of the company’s stock, valued at $12,398,792. The trade was a 11.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the business’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the transaction, the chairman directly owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This trade represents a 9.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 41,544 shares of company stock valued at $12,230,941 in the last three months. 10.80% of the stock is currently owned by insiders.

Cencora Stock Performance

Cencora stock opened at $337.60 on Friday. The company has a 50 day moving average price of $308.09 and a 200-day moving average price of $297.02. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. Cencora, Inc. has a fifty-two week low of $223.92 and a fifty-two week high of $350.46. The company has a market capitalization of $65.45 billion, a PE ratio of 34.73, a P/E/G ratio of 1.56 and a beta of 0.63.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $4.00 EPS for the quarter, topping analysts’ consensus estimates of $3.79 by $0.21. The company had revenue of $80.66 billion during the quarter, compared to the consensus estimate of $80.34 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. Cencora’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.34 earnings per share. As a group, equities analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Friday, August 15th were paid a $0.55 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.7%. Cencora’s payout ratio is 22.63%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.